InsiderTrades

Form 4 for ODTX Odyssey Therapeutics, Inc.

Accepted 2026-05-11 20:30:06 ET · period of report 2026-05-07 · accession 0001193125-26-217585 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2026-05-11 20:30 2026-05-11 ODTX Glick Gary D See Remarks, Dir C - Cnv Deriv — +27.4K 416.0K +7% —
DM 2026-05-11 20:30 2026-05-11 ODTX Glick Gary D See Remarks, Dir C - Cnv Deriv — -266.1K 0 -100% —
D 2026-05-11 20:30 2026-05-07 ODTX Glick Gary D See Remarks, Dir A - Grant $0.00 +884.5K 884.5K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-05-11 C A 27,386 — 415,973 D — — (F1) The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. (F2) The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
2 Derivative Series C Convertible Preferred Stock 2026-05-11 C D 100,000 — 0 D — · — to — 10,291 Common Stock (F1) The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. (F1) The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. (F1) The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. (F1) The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. (F3) Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering.
3 Derivative Series D Convertible Preferred Stock 2026-05-11 C D 166,116 — 0 D — · — to — 17,095 Common Stock (F2) The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. (F2) The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. (F2) The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. (F2) The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. (F3) Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering.
4 Derivative Stock Option (Right to Buy) 2026-05-07 A A 884,450 $0.00 884,450 D $18.00 · — to 2036-05-06 884,450 Common Stock (F4) Option vests in forty-eight (48) equal monthly installments, with the first installment scheduled to vest on June 7, 2026, subject to the Reporting Person's continued service on each such vesting date.